

QIBA Musculoskeletal (MSK) Biomarker Committee (BC) Meeting

Tuesday, July 25, 2023, at 10 a.m. CT

Meeting Summary

In attendance

Xiaojuan Li, PhD (Co-chair)	Natália Favoreto, MS...	Mei Li, MD	Rianne van der Heijden, MD, PhD
Thomas Link, MD, PhD (Co-Chair)	José Garcia, BS	Jing Liu, PhD	Gudrun Zahlmann, PhD
Donald Anderson, PhD	Shivraman Giri, PhD	Kecheng Liu, PhD, MBA	Yansong Zhao, PhD
Michael Boss, PhD	Peter Hardy, PhD	Nancy Obuchowski, PhD	
Angie Botto-van Bemden, PhD	Gabby Joseph, PhD	Chris Peng, PhD	RSNA
Jean H. Brittain, PhD	Youngkyoo Jung, PhD...	Atefe Pooyan, MD, MPH	Joe Koudelik
Majid Chalian, MD	Jason Kim, PhD	David Rutkowski, PhD	Susan Stanfa
Jonathan Doyle, MCS			

Topics Discussed

- Update on Calimetrix MSK phantom manufacturing timeline (Dr. Brittain)
- QIBA transition update (Dr. Chalian)
- RSNA QIBA MSK Profile Stage 3 and 4 Conformance Site Testing Updates (Dr. Li)

Action Items

Calimetrix MSK phantom manufacturing update (Drs. Brittain and Rutkowski)

- The phantom was tested, shipped, and arrived at the Cleveland Clinic (CC) on July 25
- The instruction manual was sent to the CC and can be requested from Drs. [Brittain](#) and [Rutkowski](#)

QIBA transition update and MSK BC next steps (Dr. Chalian)

- Feasible BC deliverables to be determined, as QIBA admin support and BCs will be dissolved in ~5 months
- Once formed, the new RSNA Quantitative Imaging Committee (QUIC) may initially focus on 1-3 QIBs; QUIC will reach out to BCs
- In-process Profiles to advance to nearest stage and/or summary / white paper of the Profile to be published
- QIBA brand to remain following the dissolution of the current structure; QUIC to determine process for approval of QIBA Profiles in 2024 and beyond
- QIBA Wiki will be accessible post-transition
- Comments / questions about transition plans to be submitted via [Future Direction of QIBA Activities Form](#)
- Possible natural partnerships with societies, e.g., ISMRM, ASFNR, etc. to be considered
- Progress to continue on MSK combined stage 3/4 Profile work, e.g., data collection and analysis, until and after RSNA admin support ceases
 - Multisite comparison to follow is estimated to take 1 – 2 years

Stage 3 & 4 Conformance Testing Update

- [The May 23, 2023, MSK BC Call Summary](#) contains data transfer process details
- Ambra presentation can be accessed at: <https://rsna-org.zoom.us/rec/share/BUIkT2cJNazP2O4cmzkajCd1yWwZsTymT9ZEw2jnmz87ouR8DLV6f2I0rPY1A3.Zc2YWujqi0PaWtn> | Passcode: VW9@K*.A
- Ambra to release image uploading protocol on July 26
- In order to provide data/image access to Arthritis Foundation DOA (Document of Agreement) is needed between Arthritis Foundation and all sites which should be similar for all sites, a template document should be used
- Initial QIBA scans have been performed at some sites (e.g., UCSF)

Next Steps

- Email address of person uploading data should be sent to Dr. Mei Li, who will send compiled email addresses and site numbers to Ambra for account creation
 - Link will then be provided to site contacts who will generate account and password to upload data
 - Drs. [Xiaojuan Li](#) and [Mei Li](#) can be contacted with data transfer questions or issues
- Dr. Chalian to draft a common DOA template for all sites to use
- **Next meeting:** Tuesday, August 22, 2023, at 10 a.m. CT

Participants are welcome to contact RSNA staff at giba@rsna.org if their attendance is not reflected on meeting summaries.